Abstract
Hepatorenal tyrosinaemia (HT1) is a serious condition that used to be fatal before the advent of nitisinone (NTBC, Orfadine®) as a therapeutic option. We have recently shown that selective screening is inadequate as initial symptoms are often uncharacteristic which leads to a considerable delay in diagnosis and treatment. This has a negative impact on morbidity and mortality as well as long-term outcome. For example, the odds ratio to develop hepatocellular carcinoma is 12.7 when treatment is initiated after the first birthday compared to start of treatment in the neonatal period. Timely diagnosis is only possible when neonatal mass screening is operational. HT1 meets all the criteria for neonatal mass screening at a clinical and analytical level. The natural course of the disease is well known, clinically there is a latent phase in most patients when presymptomatic treatment can be initiated. There are no mild phenotypes which do not require treatment. Using succinylacetone as the screening parameter a highly specific and sensitive test is available with acceptable financial burden. Neonatal mass screening for HT1 is acceptable to the target population as it can be performed simultaneously with the already existing screening tests in dried blood, there are no false negative and false positive cases and the financial burden to the health system is moderate. An efficient treatment is available with nitisinone and protein-reduced diet supplemented with special amino acid mixtures. Despite compelling evidence in favour of a neonatal mass screening for HT1 only 57% of European centres taking part in our recent cross-sectional study have included HT1 in their newborn screening programme.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- HT1:
-
Hepatorenal tyrosinaemia
- MS:
-
Mass spectrometry
- PKU:
-
Phenylketonuria
References
Allard P, Grenier A, Korson MS, Zytkovicz TH (2004) Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spots. Clin Biochem 37:1010–1015
Andermann A, Blancquaert I, Beauchamp S, Costea I (2011) Guiding policy decisions for genetic screening: developing a systematic and transparent approach. Publ Health Genomics 14:9–16
Bendadi F, de Koning TJ, Visser G, Prinsen HC, de Sain NG, Verhoeven-Duif N, Sinnema G, van Spronsen FJ, van Hasselt PM (2013) Impaired cognitive functioning in patiens with tyrosinemia type I receiving nitisinone. J Pediatr 164:398–401
Bonham JR (2013) Impact of new screening technologies: should we screen and does phenotype influence this decision? J Inherit Metab Dis 36:681–686
Coskun T, Ozalp I, Kocak N, Yüce A, Caglar M, Berger R (1991) Type I hereditary tyrosinaemia: presentation of 11 cases. J Inherit Metab Dis 14:765–770
Couce ML, Aldamiz-Echevarria L, Baldellou A, Blasco J, Bueno MA, Dalmau J, De La Vega A, Del Toro M, Diaz C, Lama R, Leao E, Marrero M, Navas VM, Pintos G (2010) Recomendaciones y manejo de la tirosinemia hereditaria Tipo I o Tirosinemia hepatorrenal. An Pediatr (Barc) 73(279):e1–e4
Couce ML, Dalmau J, del Toro M, Pintos-Morell G, Aldamiz-Echevarria (2011) Tyrosinemia type I in Spain: mutational analysis, treatment and long-term outcome. Pediatr Int 53:985–989
De Laet C, Munoz VT, Jaeken J, Francois B, Carton D, Sokal EM, Dan B, Goyens PJ (2011) Neuropsychological outcome of NTBC-treated patients with tyrosinaemia type 1. Dev Med Child Neurol 53:962–964
Jakob C, Dorland L, Wikkering B, Kok RM, de Jong APJM, Wadman SK (1988) Stable isotope dilution analysis of succinylacetone using eletrone capture negative ion mass fragmentography: an accurate approach to the pre-neonatal diagnosis of hereditary tyrosinemia type I. Clin Chim Acta 171:223–223
Larochelle J, Alvarez F, Bussières JF, Chevalier I, Dallaire L, Dubois J, Faucher F, Fenyves D, Goodyer P, Grenier A, Holme E, Laframboise R, Lambert M, Lindstedt S, Maranda B, Melancon S, Merouani A, Mitchell J, Parizeault G, Pelletier L, Phan V, Rinaldo P, Scott CR, Scriver C, Mitchell GA (2012) Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec. Mol Genet Metab 107:49–54
Loeber JG, Burgard P, Cornel MC, Rigter T, Weinreich SS, Rupp K, Hoffmann GF, Vittozzi L (2012) Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 1. From blood spot to screening result. J Inherit Metab Dis 35(4):603–611
Magera MJ, Gunawardena ND, Hahn SH, Tortorelli S, Mitchell G, Goodman SI, Rinaldo P, Matern D (2006) Quantative determination of succinylacetone in dried blood spots for newborn screening of tyrosinemia type I. Mol Genet Metab 88:16–21
Masurel-Paulet A, Poggi-Bach J, Rolland MO, Bernard O, Guffon N, Dobbelaere D, Sarles J, de Baulny HO, Touaty G (2008) NTBC-treatment in tyrosinaemia type I: long-term outcome in French patients. J Inherit Metab Dis 31:81–87
Mayorandan S, Meyer U, Gokcay G, Segarra NG, de Baulny HO, van Spronsen F, Zeman J, de Laet C, Spiekerkoetter U, Thimm E, Maiorana A, Dionisi-Vici C, Moeslinger D, Brunner-Krainz M, Lotz-Havla AS, Cocho de Juan JA, Couce Pico ML, Santer R, Scholl-Bürgi S, Mandel H, Bliksrud YT, Freisinger P, Aldamiz-Echevarria LJ, Hochuli M, Gautschi M, Endig J, Jordan J, McKiernan P, Ernst S, Morlot S, Vogel A, Sander J, Das AM (2014) Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice. Orphanet J Rare Dis 9:107
Mohan N, McKiernan P, Preece MA, Green A, Buckels J, Mayer AD, Kelly DA (1999) Indications and outcome of liver transplantation in tyrosinaemia type 1. Eur J Pediatr 158(Suppl 2):S49–S54
Pohorecka M, Biernacka M, Jakubowska-Winecka A, Biernacki M, Kusmierska K, Kowalik A, Sykut-Cegielska J (2012) Behavioral and intellectual functioning in patients with tyrosinemia type I. Pediatr Endocrinol Diabetes Metab 18:96–100
Sander J, Janzen N, Peter M, Sander S, Holtkamp U, Schwahn B, Mayatepek E, Trefz FK, Das AM (2006) Newborn screening or hepatorenal tyrosinemia: tandem mass spectrometric quantification of succinylacetone. Clin Chem 52:482–487
Schiff M, Broue P, Chabrol B, De Laet C, Habes D, Mention K, Sarles J, Spraul A, Valayannopoulos V, Baulny H (2011) Heterogneity of follow-up procedures in French and Belgian patients with treated hereditary tyrosinemia type I: results of a questionnaire and proposed guidelines. J Inherit Metab Dis 35:823–829
Thimm E, Richter-Werkle R, Kamp G, Molke B, Herebian D, Klee D, Mayatepek E, Spiekerkoetter U (2012) Neurocognitive outcome in patients with hypertyrosinemia type I after a long-term treatment with NTBC. J Inherit Metab Dis 35:263–268
Vondrakova A, Tesarova M, Magner M, Docekalova D, Chrastina P, Prochazkova D, Zeman J, Honzik T (2010) Clinical, biochemical and molecular characteristics in 11 Czech children with tyrosinemia type I. Cas Lek Cesk 149:411–416
Wilson JMG, Jungner G (1968) Principles and practice of screening for disease. Public Health Pap 34:26–35
Zytkovicz TH, Sahai I, Rush A, Odewale A, Johnson D, Fitzgerald E, Britton D, Eaton RB (2013) Newborn screening for hepatorenal tyrosinemia – I by tandem mass spectrometry using pooled samples: a four-year summery by the New England newborn screening program. Clin Biochem 46(7–8):681–684
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Das, A.M., Mayorandan, S., Janzen, N. (2017). Diagnosing Hepatorenal Tyrosinaemia in Europe: Newborn Mass Screening Versus Selective Screening. In: Tanguay, R. (eds) Hereditary Tyrosinemia. Advances in Experimental Medicine and Biology, vol 959. Springer, Cham. https://doi.org/10.1007/978-3-319-55780-9_11
Download citation
DOI: https://doi.org/10.1007/978-3-319-55780-9_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-55779-3
Online ISBN: 978-3-319-55780-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)